Inogen (INGN) Earnings Date & Reports

Key Takeaways

• Inogen reported third quarter 2026 revenue of $77.2 million, down 2.4% from $79.1 million in the prior-year period.
• U.S. sales rose 3.8% to $42.2 million, marking the first year-over-year U.S. growth since the fourth quarter of 2024.
• International sales fell 9% to $34.9 million, pressured by softer capital spending among large European customers.
• Adjusted net loss from continuing operations was $0.4 million, compared with adjusted earnings of $1.2 million a year earlier.
• The company closed the divestiture of its U.S. oxygen rental business and announced a $20 million cost savings program.
• Inogen guided fourth quarter 2026 revenue to $65 million–$68 million and full-year 2026 revenue to $298 million–$301 million.
• You can find more information about Inogen's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Explore Trending AI Robots to see how AI-driven trading tools are navigating current market conditions.

Earnings Context and Why It Matters

Inogen, a medical technology company that develops portable oxygen concentrators (POCs, which are lightweight devices that deliver supplemental oxygen to patients), reported third quarter 2026 results amid a significant strategic restructuring. The company has now exited its U.S. oxygen rental business and is refocusing on its core product portfolio and adjacent respiratory markets. This earnings report matters because it offers investors the first clear look at Inogen's continuing operations after the divestiture, alongside new leadership under a recently appointed chief executive officer. With a market-leading position in portable oxygen, Inogen's ability to reignite U.S. growth, stabilize European demand, and convert cost cuts into profitability will be central to the investment case going forward.

Reported Results

For the third quarter of 2026, Inogen reported total revenue of $77.2 million, a 2.4% decline from $79.1 million in the prior-year period. U.S. sales increased 3.8% to $42.2 million, driven by distributor demand and contributions from new products, while international sales decreased 9% to $34.9 million on softer capital spending among several large European customers. Overall POC unit volume rose nearly 6% year over year to 51,900 units.

Adjusted gross margin was 44.2%, down from 45.9% a year earlier, reflecting lower international sales partially offset by manufacturing cost improvements. GAAP (Generally Accepted Accounting Principles) loss from continuing operations was $14.8 million, which included a $10.6 million non-cash goodwill impairment. On an adjusted basis, the company reported a net loss from continuing operations of $0.4 million, versus adjusted earnings of $1.2 million in the prior-year period. Adjusted net loss per diluted share was $0.02, compared with adjusted earnings of $0.04 a year earlier. Inogen ended the quarter with $97.7 million in cash, cash equivalents, marketable securities, and restricted cash, and no debt outstanding.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following healthcare and medical technology names like Inogen, it offers a structured way to surface comparable opportunities across the broader market.

Market Reaction and Investor Sentiment

Investor reaction to Inogen's third quarter report will likely hinge on two competing signals. On one hand, the return of U.S. sales growth and the announced cost savings program point toward a more focused, leaner company. On the other hand, the continued international softness, the goodwill impairment charge, and the near-term revenue decline underscore the challenges the company still faces in converting its restructuring into consistent profitability. The divestiture of the rental business simplifies the operating model, but it also removes a revenue stream and shifts reported results to a continuing-operations basis, which can complicate year-over-year comparisons. Market participants will be watching whether the company's cost discipline and new product momentum can offset persistent European weakness in the quarters ahead.

Forward Outlook and Key Factors to Monitor

Inogen provided fourth quarter 2026 revenue guidance of $65 million to $68 million and full-year 2026 revenue from continuing operations of $298 million to $301 million. The company expects a full-year 2026 adjusted net loss from continuing operations of $7 million to $8 million, signaling that profitability remains a work in progress.

Several factors will shape the path forward. First, investors should monitor whether U.S. sales can sustain their return to growth as new products gain traction and distributor partnerships strengthen. Second, European demand remains a key swing factor, with management indicating that the softness in capital spending could continue into the fourth quarter.

Third, the $20 million cost savings program, expected to generate annualized savings by the end of 2027 with roughly $10 million completed before the end of 2026, will be closely watched for its impact on the bottom line. Fourth, Inogen's expansion into adjacent respiratory markets, including sleep and airway clearance, represents a longer-term growth opportunity but is still in its early stages. Together, these dynamics will determine whether Inogen can translate its simplified structure into sustainable, profitable growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations